Company intelligence / Profile preview

Ambio

North Augusta, South Carolina, United States

Ownership: Private
Employees: ~600
Development stage: Other

Overview

Ambio develops peptide-based biosimilar, bioequivalent and complex generic drugs, with at least one AAV-based gene therapy program using peptide ShK-235 targeting Kv1.3 in preclinical development for obesity and obesity-related metabolic disease, and expects multiple biosimilar peptide launches from 2024 onward.[1][5]

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Partnerships with leading pharmaceutical companies for biosimilar and complex generic peptide drugs (undisclosed partners)Multiple biopharma customers for peptide API CDMO services worldwide

Beyond the preview

Go deeper on Ambio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambio.

Explore the full profile